文献速递肿瘤 PET/CT核素与放射性配体治疗

68Ga-PSMA-PET/CT引导下立体定向放疗治疗去势抵抗性前列腺癌寡进展病灶

Stereotactic radiotherapy to oligoprogressive lesions detected with 68Ga-PSMA-PET/CT in castration-resistant prostate cancer patients.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2021-03-10

该回顾性研究分析了67例去势抵抗性前列腺癌(CRPC)患者共133个寡进展病灶,均接受基于68Ga-PSMA-PET/CT的立体定向体部放疗(SBRT)。中位随访17.5个月,2年总生存率和无进展生存率分别为86.9%和34.4%,PSA应答率73.1%,未观察到严重急性或晚期毒性。研究表明该转移导向治疗可行、有效且耐受良好,通过延迟下一线系统性治疗(NEST)延长了雄激素剥夺治疗(ADT)的效用。

要点

  • 68Ga-PSMA-PET/CT引导SBRT治疗CRPC寡进展病灶,2年OS率86.9%、PFS率34.4%。
  • PSA应答率73.1%,中位11.0个月时55.2%患者出现进展。
  • SBRT前PSA较高是OS和NEST-FS较差的唯一显著预测因素。

核心结论

  • 基于68Ga-PSMA-PET/CT的SBRT治疗CRPC寡进展病灶可行、有效且耐受良好,通过延迟NEST延长ADT效用。

研究设计与样本

  • 回顾性分析67例接受68Ga-PSMA-PET/CT引导SBRT的CRPC患者共133个寡进展病灶,所有患者均在ADT期间出现寡进展。
  • 分析总生存(OS)和无进展生存(PFS)的预后因素,以及切换至下一线系统性治疗(NEST)和NEST无生存(NEST-FS)的预测因素。

主要发现

  • 中位随访17.5个月,2年OS率为86.9%,2年PFS率为34.4%。
  • 49例(73.1%)患者观察到PSA应答。
  • 37例(55.2%)患者在中位11.0个月时出现进展。
  • 45例(67.2%)患者在SBRT后继续ADT,22例(32.8%)在中位16.4个月时发生NEST切换。
  • 发生NEST切换的患者SBRT后PSA值更高,且MDT后PSA最低值更少。

临床怎么用

  • 对于ADT期间出现≤5个寡进展病灶的CRPC患者,可考虑68Ga-PSMA-PET/CT引导的SBRT作为转移导向治疗,以延迟下一线系统性治疗。
  • SBRT前PSA较高提示OS和NEST-FS较差,可作为预后评估参考。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We assessed the outcomes of stereotactic body radiotherapy (SBRT) to treat oligoprogressive castration-resistant prostate cancer (CRPC) patients with ≤5 lesions using gallium prostate-specific membrane antigen-positron emission tomography (68Ga-PSMA-PET/CT). METHODS: The clinical data of 67 CRPC patients with 133 lesions treated with 68Ga-PSMA-PET/CT-based SBRT were retrospectively analyzed. All of the patients had oligoprogressive disease during androgen-deprivation therapy (ADT). The prognostic factors for overall- (OS) and progression-free survival (PFS) and the predictive factors for switching to next-line systemic treatment (NEST) and NEST-free survival (NEST-FS) were analyzed. RESULTS: With a median follow-up of 17.5 months, the 2-year overall survival (OS) and PFS rates were 86.9% and 34.4%, respectively. The PSA response was observed in 49 patients (73.1%). Progression was observed in 37 patients (55.2%) at a median of 11.0 months following SBRT. A total of 45 patients (67.2%) remained on ADT after SBRT, and 22 patients (32.8%) had a NEST change at a median of 16.4 months after metastasis-directed treatment (MDT). Patients with a NEST change had higher post-SBRT PSA values and fewer PSA nadirs after MDT than their counterparts. In multivariate analysis, higher pre-SBRT PSA values were the only significant predictor for worse OS and NEST-FS, and no significant factor was found for PFS. No serious acute or late toxicities were observed. CONCLUSION: This study demonstrated the feasibility of MDT using SBRT to treat oligoprogressive lesions by 68Ga-PSMA-PET/CT in CRPC patients is efficient and well-tolerated, prolonging the effectiveness of ADT by delaying NEST.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Onal C, Ozyigit G, Oymak E, et al. Stereotactic radiotherapy to oligoprogressive lesions detected with 68Ga-PSMA-PET/CT in castration-resistant prostate cancer patients. Eur J Nucl Med Mol Imaging. 2021. PMID: 33693965. doi:10.1007/s00259-021-05298-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。